Pyramid Analytics Ascends to the Large / Enterprise-Wide Implementations Category in BARC BI & Analytics 22 Report
11.11.2021 16:00:00 EET | Business Wire | Press release
Pyramid Analytics announced today that BARC (Business Application Research Center), a leading European analyst firm, elevated Pyramid’s Decision Intelligence Platform to the Large/Enterprise-Wide Implementations category. Pyramid received 40 Top Rankings (1st place) and 87 Leading Positions (place top 22-33% or top 2 products in its 6 peer groups) in The BI & Analytics Survey 22. Based on a sample of 2,478 survey responses, the BARC report offers an unsurpassed level of user feedback on 30 leading business intelligence (BI) solutions. BARC is one of Europe’s leading analyst firms for business software, focusing on the areas of data, business intelligence and analytics (ABI).
Key Points:
- 100 percent of customers surveyed would recommend Pyramid Analytics.
- 97 percent of users rate Pyramid’s functionality for creating dashboards as excellent or good, beating the average rating by 82 percent.
- 91 percent of users rate Pyramid Analytics’ vendor support as excellent or good. This is in sharp contrast with just 65 percent for the average BI tool.
- 88 percent of users rate Pyramid Analytics’ price to value as excellent or good; notably higher than the 71 percent for average tools.
- Download the complimentary report.
BARC Net Assessment
“It has been another great year for Pyramid Analytics, scoring 40 top ranks and 87 leading positions across its six peer groups. Pyramid performed especially well in comparison to its rivals in the Large/Enterprise-Wide Implementations peer group, where half of its top ranks came,” the report’s authors wrote, adding that “Pyramid customers clearly benefit from using the software. We asked customers to rate their level of achievement of 11 different business benefits. Pyramid scored well above average in almost all these benefits. Compared to other vendors in the survey, Pyramid customers are especially likely to be able to reduce costs, improve customer satisfaction, and improve operational efficiency.”
BARC determined that the Pyramid Analytics Decision Intelligence Platform deployments, use cases, functionality, and performance met its requirements for Enterprise-Wide Implementations; is well-suited to support a broad range of BI and analytics use cases and large numbers of end-users in multiple roles; and is capable of managing Big Data without compromising critical factors such as query response time, flexible self-service, and ease of use.
Complete, Integrated Decision Intelligence
Only Pyramid’s Decision Intelligence Platform unifies Data Preparation, Business Analytics, and Data Science on a single, integrated platform. This eliminates the need to use disparate, multiple tools and the associated license cost and management complexity. Lower Total Cost of Ownership (TCO), rapid rollout, and industry-leading user adoption means faster time to value.
The Pyramid Analytics Decision Intelligence Platform can be deployed on-premises, into a private or public cloud, embedded into other apps from Original Equipment Manufacturers (OEM) and Independent Software Vendors (ISV) or delivered through Managed Services Providers (MSP).
Voice of the Customer
- “A powerful platform with an abundance of well-thought out, integrated features and functionality. Fast, modern and sophisticated without being complicated.” Head of BI & Analytics Competence Center, Retail Industry, >2,500 employees
- “A polished product supported by an enthusiastic and knowledgeable team.” CIO, Energy Industry, >2,500 employees
- “A great product. Flexible and excellent self-service [BI & Analytics].” BI/Analytics Leader, Manufacturing Industry, >2,500 employees
Quotes
- Carsten Bange, Founder and CEO, BARC: “If you are considering buying a BI product, you really need to know how other users and organizations rate it. The BI & Analytics Survey 22 captures what end users really think about the BI products they use. Input from Pyramid Analytics customers and our own assessment of its ABI platform revealed continued innovation. Pyramid Analytics is a growing vendor with an increasing presence in the market. Its product is highly competitive, as the results in The BI & Analytics Survey 22 show. It is therefore unsurprising to see it has a high win rate when competing for new deals. I am eager to watch their progress over the next year.”
- Omri Kohl, CEO & Co-Founder, Pyramid Analytics: “We place tremendous value on The BI & Analytics Survey because BARC provides a painstakingly thorough analysis and, importantly, draws from real-world, hands-on experience. I thank Carsten and his team for their diligent research. And I am proud that the Pyramid Analytics Decision Intelligence Platform is again top-ranked or in a leadership position in all categories that mean the most to enterprise customers.”
Download a complimentary copy of Pyramid highlights in The BI & Analytics Survey 22 from BARC now.
About The BI & Analytics Survey 22
The BI & Analytics Survey 22 was conducted by BARC from March to June 2021. Altogether, 2,487 respondents worldwide answered a series of questions about their BI and analytics software. The survey offers a comparison of 30 leading business intelligence tools across 36 key performance indicators including Business Value, Customer Satisfaction, Customer Experience and Competitiveness. For more information, go to www.bi-survey.com.
About Pyramid Analytics
The Decision Intelligence Platform from Pyramid Analytics enables enterprises in any industry to maximize the value of data by unifying Data Preparation, Business Analytics, and Data Science in a single Analytics and Business Intelligence (ABI) infrastructure. By balancing performance and ease of use, everyone from business users to the most advanced data scientists get real-time, direct self-service access to reliable data from any domain or source, customized reports, and clear, actionable analysis. Flexible deployment options include on-premises and multi-cloud and hybrid environments. Schedule a demo.
Pyramid Analytics has offices in global innovation and business centers, including Amsterdam, London, New York City (US HQ), and Tel-Aviv, Israel. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Learn more at Pyramid Analytics.
The Pyramid Decision Intelligence Platform. Know What’s Next.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005534/en/
Contact information
Chas Kielt
Vice President of Corporate Communications | Product and Partner Marketing, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
